Regeneron beats results estimates on demand for eczema treatment, eye drug
Oct 31 (Reuters) -U.S. drugmaker Regeneron Pharmaceuticals REGN.O beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea.
Regeneron has been looking to upgrade patients who use Eylea to a high-dose version, as the drug that has long been its cash cow faces the threat of biosimilar products and stiff competition from rivals, including Roche's ROG.S Vabysmo.
Swiss drugmaker Rochereaffirmed its full-year profit forecast while beating quarterly estimates for sales last week, banking on strong demand for Vabysmo.
Total U.S. net sales of Eylea, jointly developed with Bayer AG BAYGn.DE, rose 3% to $1.54 billion, including $392 millionfrom the higher, 8-milligram dose version of the drug.
The high-dose version of the eye disease drug was launched in August 2023 and allows for longer intervals between injections for patients.
Regeneron's total revenue of $3.72 billionbeat expectations of $3.67 billion, according to data compiled by LSEG.
The drugmaker's anti-inflammatory drug Dupixent posted sales of $3.82 billion, beating estimatesof $3.78 billion. French partner Sanofi SASY.PA records Dupixent sales and profits are split equally between the companies.
Dupixent is currently approved to treat six disease types including asthma, a skin condition called atopic dermatitis and most recently as an add-on treatment for chronic obstructive pulmonary disease.
The company reported an adjusted profit of $12.46per share for the quarter, above estimatesof $11.69 per share.
Reporting by Christy Santhosh in Bengaluru; Editing by Devika Syamnath
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
